We have recently discovered bovine and human vascular smooth muscle cells (SMCs) express a novel constitutive Nuclear Factor-cB (NF-cB)/Rel-like activity (Lawrence, R., L.-J. Chang, U. Siebenlist, P. Bressler, and G. E. Sonenshein. 1994. J. Biol Chem. 269:28913-28918), here termed SMC-Rel. Since cytomegalovirus (CMV) infection of human vascular SMCs has been implicated in aberrant SMC proliferation during post-angioplasty restenosis, we tested the role of NF-icB/Rel activity in transactivation of the CMV immediate early (ie) promoter. The basal CMV ie promoter linked to three wild-type, but not mutant, copies of its NF-#cB element was active in bovine aortic SMCs.
Introduction
Members of the NF-KB '/Rel family of transcription factors play important roles in the regulation of transcription of a variety of 1 . Abbreviations used in this paper: /3-gal, /6-galactosidase; CAT, chloramphenicol acetyl transferase; CMV, cytomegalovirus; ie, immediate early gene of CMV; IKB-a, NF-KB inhibitor-a; NAC, N-acetyl cysteine; NF-KB, Nuclear Factor-KB; PTX, pentoxifylline; SMC, smooth muscle cell; SMC-Rel; novel constitutive Rel-like subunit expressed in SMCs.
cellular and viral genes, including the c-myc oncogene ( 1, 2), several interleukins, receptors and adhesion molecules, and genes of the HIV-1 (for reviews see references 3 and 4) and cytomegalovirus (CMV) (5, 6) . NF-KB activity can be induced in a wide variety of cell types in response to treatment with such agents as IL-1, TNFa, adhesion, oxidative stress, and oxidized LDL (3, 4) . The inducible NF-KB/Rel activity is due to release of sequestered cytoplasmic NF-KB from inhibitor IKB proteins (7, 8) . In this manner, NF-KB/Rel family members can serve as important second messengers in signal transduction. Constitutive nuclear NF-KB activity appeared to occur only in mature B cells, activated T cells and monocytes, and neurons, but we recently demonstrated bovine and human vascular SMCs express an NF-KB-like activity constitutively (9) . This factor activated transcription of a heterologous promoter driven by mutimerized elements of the immunoglobulin kappa light chain or the c-myc gene, as well as the HIV long terminal repeat. Despite extensive efforts to identify this activity as one of the previously identified Rel-family members, we have been unable to do so, raising the possibility that this factor is a novel SMCspecific member of the NF-KB/Rel family (now termed SMC-Rel).
Vascular smooth muscle cells are a major constituent of the medial layer of blood vessels and have been implicated in the development of atherosclerotic plaques (10) . Aberrant proliferation within the intima following injury leads to excessive production of extracellular matrix and contributes to the occlusion of the arteries. In addition, in 25-50% of patients receiving coronary angioplasty, a process called restenosis involving significant SMC proliferation occurs which often leads to reclosure of the vessel (10) . An understanding of the mechanisms by which SMC growth is regulated is crucial to the development of effective treatments for these disorders. In light of a recent report demonstrating that aberrant SMC proliferation in postangioplasty restenosis may be a result of CMV infection and consequent stabilization of the tumor suppressor p53 (11), we sought to determine whether constitutive SMC NF-KB/Rel factors might play a role in the activation of the CMV immediate early (ie) gene promoter through its NF-KB sites. Using transient transfection, here we report that the NF-KB elements play a significant role in constitutive activation of the CMV ie gene promoter in bovine aortic SMCs. Addition of anti-oxidants, that have been found to inhibit NF-KB/Rel activity (4), caused a decrease in transactivation of CMV promoter and NF-KB element driven constructs that could be related to a decline in Methods Cell culture. Vascular SMCs were obtained by explant of bovine aorta as previously described (9) and grown in Dulbecco-Vogt minimal essential medium (DMEM) supplemented with 4 mM glutamine, 50 U/ml penicillin, 50 og/ml streptomycin and 10% fetal bovine serum (GIBCO Laboratories, Grand Island, NY). These cells, which have a synthetic phenotype and express only very low levels of SMC actin, were used within the fourth passage. Bovine aorta endothelial cells, kindly provided by D. Larson, were similarly cultured. SMCs were rendered quiescent by growth to confluence as described (9) . Interleukin-1 (IL-1) and interleukin 6 (IL-6) (kindly provided by J. Sipe) were added to 10 ng/ ml for 1 h before preparation of nuclear extracts. N-acetyl cysteine (NAC) (Sigma Chemical Co., St. Louis, MO) was prepared as a 200 mM stock in DMEM and adjusted to pH 7.3 with 1 N NaOH immediately before addition to cells. Pentoxifylline (PTX) (Sigma) was prepared as a 100 mM stock in DMEM.
Transfection and reporter gene assays. For the CMV constructs, cells were transfected by the modification of the calcium phosphate method described by Chen and Okiyama (12 DNA, which is optimal for transfection of SMCs under these conditions. CAT assays were performed on protein extracts using a continuous fluor diffusion assay (13), as we have described previously (9) . Extracts, normalized for transfection efficiency, were subsequently assayed for /3-galactosidase activity (14) . In addition, constructs containing two copies of wild type or mutated versions of the NF-KB element (URE from upstream of the c-myc promoter) linked to the thymidine kinase (TK) promoter driving the CAT plasmid, described previously (9) GATCCAAGTCCGGG'lI'7CCCCAACC mUREl: GATCCAAGTCCGCC'llTTCCCCAACC mURE2: GATCCAAGTCCGGGTTCCCCCCAACC mURE3: GATCCAAGTCCGGG'lT'lGGCCAACC mURE4: GATCCAATGAAGGGT'TYl'CCCCAACC. The region critical for binding, indicated by methylation interference (1) and mobility shift analysis (9) , is underlined in the wild-type URE sequence. The mutations, indicated in bold font, are in the binding region in mutants 1, 2, and 3 and outside of the core binding region in mutant 4 . The oligonucleotide containing the NF-KB element from the kappa light chain gene was CAGAGGGGACTTTCCGAGAGG (3).
For AP-1 binding, the double stranded oligonucleotide (with binding site underlined) used was: GATCGCCATGTGACTCATTAC.
Electrophoretic mobility shift assay. Nuclear extracts were prepared by a "miniprep" procedure described previously (15) , and quantitated for protein, as above. Oligonucleotides were 32P-labeled to an approximate specific activity of 6000 Ci/mmol and purified by polyacrylamide electrophoresis. Nuclear extract (5 Mg) was mixed with 10 Itg poly (dIdC) (Pharmacia, Piscataway, NJ) and 25,000 dpm of labelled doublestranded oligonucleotide in 2 mM Hepes pH 7.5, 1 mM dithiothreitol, 0.1% Triton X-100, 0.5% glycerol, and 100 mM KCl in a volume of 25 M1 and incubated at 230C for 30 min. DNA-protein complexes were resolved by nondenaturing polyacrylamide electrophoresis in 4.5% acrylamide, employing as buffer 0.022 M Tris-borate, 0.5 mM EDTA (9) .
Determination of the number of cells in S phase. Photomicrography. Cells were photographed using a Nikon FM2 camera with technical pan film (ASA 25) using automatic exposure.
Results
NF-KB/Rel elements play a role in activation ofthe CMV immediate early promoter in SMCs. To determine whether the constitutive NF-KB/Rel-like factor could activate transcription of the CMV ie promoter, transient transfection analysis was performed using CMV promoter-lac Z reporter constructs. As control, MoECAT, a CAT gene under the control of the Moloney Murine Leukemia Virus long terminal repeat, was co-transfected and extracts normalized for transfection efficiency. The full length CMV ie promoter-lacZ reporter construct (pON405) was very active after transient transfection into SMCs compared to the pON407 construct, in which much of the promoter including all copies of the CMV NF-KB sites had been deleted (Fig. 1) . This result contrasts with findings by Mocarski and co-workers with fibroblasts or T cells, in which these promoters gave comparable, low levels of activity and only the pON405 gave significant activity following induction of NF-KB (5, 6). The pON407.18R3 construct, in which three tandem copies of the CMV NF-KB sites were added to pON407, had more than tenfold higher activity than its parental construct. In contrast, pON407.18 (T1TT)R3, which has three copies of a mutated version of the NF-KB site, exhibited levels indistinguishable from pON407. These data suggest that part of the activity of the CMV promoter is mediated through its NF-KB sites. To test for inhibition of induction of NF-KB, some cell cultures were then administered IL-I or IL-6 for 1 h, and nuclear extracts prepared. Electrophoretic mobility shift analysis was performed using a double-stranded (ds) oligonucleotide containing the NF-KB site upstream of the murine c-myc promoter (URE). Nuclear extracts from untreated SMCs yielded two bands in mobility shift analysis, as expected (Fig. 2) . The bottom band contains p50 homodimers, which have been found unable to activate transcription in vivo (1, 3, 4) , and the upper band appears to represent a heterodimer of p50 and a second, as yet unidentified Rel subunit (9) , designated SMC-Rel. NAC treatment significantly lowered the basal levels of binding activity to the URE. In contrast no decline was observed in binding to an AP-1 oligonucleotide used as a control for equal protein loading (data not shown). Both IL-1 and IL-6 induced NF-KB/Rel binding NAC: ---IL-1: -+ -IL-6: --+ Figure 2 . NAC downregulates basal SMC-Rel activity. Nuclear extracts, prepared from control (untreated) SMCs or from cultures pretreated with NAC at 20 mM for 21.5 h, then treated for one hour with 10 ng/ml IL-I or 10 ng/ml IL-6, as indicated, were used in electrophoretic mobility shift analysis with the ds URE NF-KB oligonucleotide. The indicated upper and lower complexes represent: p50/SMC-Rel and p50 homodimer, respectively. activity in SMCs. A major new band arises that has been found to supershift with antibodies specific for the p50 and p65 subunits (data not shown), and thus this band is likely to represent classical NF-KB (p5O/p65) (3, 4) . In addition, a slight increase was noted in p50/SMC-Rel binding. The levels of activity obtained after treatment with IL-I were reduced by NAC. In contrast, the inducible level obtained by IL-6 treatment was unaffected, suggesting perhaps that the mechanism of activation may not be sensitive to antioxidants. Thus NAC, an inhibitor of NF-KB activation, lowers levels of constitutive SMC NF-KB/Rel factor binding.
NAC inhibits SMC NF-KB/Rel functional activity. To test the effects of NAC on the functional activity of SMC NF-KB/ Rel, transient transfection assays were performed. SMCs, pretreated with NAC for 20 h, were co-transfected with the CMV constructs, as above, and 3-gal activity compared with untreated controls (Fig. 3) . NAC treatment dramatically reduced the activity of the full length CMV ie promoter and the pON407.18R3 basal promoter driven by three wild-type NF-KB element con- (Table II) . SMCs maintained in these drugs for 5 d resumed growth when returned to normal medium (data not shown). In contrast, the inhibitory effects of 10 mM NAC are not seen in vascular endothelial cells, which do not express a constitutive NF-KB/Rel activity (Fig. 5) . Furthermore, vascular endothelial cells experienced no inhibition of DNA synthesis with NAC treatment at this dose (data not shown). Thus, NAC and PTX, two drugs which inhibit SMC NF-KB/Rel activity, inhibit SMC proliferation. Microinjection of SMC with purified IKB-a inhibits SMC proliferation. To confirm a direct role of SMC NF-KB/Rel activity in proliferation, we microinjected SMCs with purified IKB-a, a naturally occurring inhibitor of NF-KB (7, 8). Our previous experiments had shown that the binding of complexes containing the SMC-Rel factor was prevented by the presence of this inhibitor (9) . Exponentially growing SMCs were microinjected with IKB-a or as control bovine serum albumin (BSA) at concentration of 1 yglyl. Assuming a microinjection volume of 10-11 ml and a molecular weight of 37 kD for this protein, we estimate that -150,000 molecules of IKB-a were introduced into the SMC. Cells were labelled for 8 h with [3H]-thymidine 16 h after microinjection, and processed for autoradiography. Table III shows that microinjection of IKB-a inhibited Microinjected NF-KB oligonucleotides inhibit SMC proliferation. As another measure of the specificity of inhibition of NF-KB/Rel binding on SMC proliferation, oligonucleotides harboring wild-type and mutant NF-KB sequences were microinjected into the SMCs. Recent data has demonstrated that microinjection of ds oligonucleotide harboring a transcription factor binding site can compete in vivo and inhibit the activity of the factor (18) . SMCs were microinjected with ds wild-type NF-KB oligonucleotides from the c-myc gene (URE) or the kappa light chain gene (KB), which have both been shown to be functional within these cells (9) . As controls for specificity for the effects, the series of four mutant URE oligonucleotides (19) (20) (21) ; similar antisense technologies targetting the SMC-Rel factor in the region of angioplasty might be predicted to inhibit SMC proliferation and restenosis. However, this approach has proven difficult to develop for in vivo use. Our finding that agents such as NAC and PTX, which are currently in clinical use for other purposes, inhibit vascular SMC proliferation might permit an easier, pharmacologic approach for the treatment of atherosclerosis, restenosis, and other diseases involving hyperproliferation of SMCs. Other antioxidants, which have been found to inhibit activity (4) may also be effective. Of note, we have recently demonstrated that human uterine SMCs, including both normal human myometrium and uterine leiomyoma (fibroids) express constitutive NF-KB-like activity (R. Bellas, R. Weiss, and G. Sonenshein, manuscript in preparation).
It has been shown that the antioxidants probucol and butylated hydroxytoluene are effective in reducing plaque formation in animal models of atherosclerosis (22) (23) (24) (25) (26) (27) . It has been suggested these drugs have been successful because of their ability to lower oxidized-LDL levels. However, our findings raise the possibility that these drugs may also affect SMC NF-KB/Rel activity and thus directly inhibit SMC proliferation. Furthermore, recent evidence has leant strong support to a longstanding notion that atherosclerosis and CMV infection may be associated (reviewed in reference 28). In a large percentage of restenosis lesions from patients, CMV infection correlated with inactivation of the tumor suppressor p53 ( 11), thereby subverting normal SMC growth control. We have found that the CMV ie promoter is activated by the NF-KB-like activity in SMCs. Thus therapies targetting the SMC-Rel factor may be able to elicit two very different benefits: interference with CMV replication, and direct inhibition of SMC growth.
